Lexaria Bioscience Corp. LEXX
We take great care to ensure that the data presented and summarized in this overview for Lexaria Bioscience Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LEXX
View all-
Invenomic Capital Management LP Boston, MA473KShares$1.48 Million0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA99.3KShares$309,9340.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA85.2KShares$265,6860.0% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL39.6KShares$123,3960.0% of portfolio
-
State Street Corp Boston, MA39.3KShares$122,6190.0% of portfolio
-
Adar1 Capital Management, LLC Austin, TX26.6KShares$83,0730.02% of portfolio
-
Welch Group, LLC24KShares$74,8800.0% of portfolio
-
Morgan Stanley New York, NY23.4KShares$72,8640.0% of portfolio
-
Northern Trust Corp Chicago, IL18.4KShares$57,3730.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il15.9KShares$49,4700.0% of portfolio
Latest Institutional Activity in LEXX
Top Purchases
Top Sells
About LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Insider Transactions at LEXX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 14
2024
|
Vanessa Carle Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+49.34%
|
$2,500
$1.15 P/Share
|
|
Feb 09
2023
|
Catherine C. Turkel Director |
BUY
Open market or private purchase
|
Direct |
1,500
+50.0%
|
$3,000
$2.84 P/Share
|
|
Oct 14
2022
|
Gregory Downey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
121
+5.83%
|
$242
$2.09 P/Share
|
|
Oct 13
2022
|
Christopher Bunka Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
16,600
+6.13%
|
$33,200
$2.1 P/Share
|
|
Oct 12
2022
|
Christopher Bunka Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
21,900
+8.43%
|
$21,900
$1.99 P/Share
|
|
May 24
2022
|
Albert L Reese Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+31.41%
|
$5,000
$1.96 P/Share
|
|
May 20
2022
|
Albert L Reese Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,799
+23.32%
|
$3,598
$2.01 P/Share
|
|
May 19
2022
|
Albert L Reese Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,501
+26.71%
|
$3,002
$2.01 P/Share
|
|
May 18
2022
|
Albert L Reese Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,700
+39.38%
|
$3,400
$2.01 P/Share
|
|
Nov 10
2020
|
Christopher Bunka Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
41,500
+0.21%
|
$0
$0.2 P/Share
|
|
Nov 09
2020
|
Christopher Bunka Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
94,000
+0.24%
|
$0
$0.21 P/Share
|
|
Nov 06
2020
|
Christopher Bunka Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
60,000
+0.94%
|
$0
$0.21 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 2.5K shares |
|---|